Valneva’s Promising Growth and Strategic Positioning: Buy Rating Affirmed by Edward White

H.C. Wainwright analyst Edward White reiterated a Buy rating on Valneva (VALN – Research Report) today and set a price target of $17.00.

Edward White has given his Buy rating due to a combination of factors that highlight Valneva’s promising growth trajectory and strategic positioning. The company demonstrated robust financial performance with a 13% increase in product sales year-over-year, despite facing challenges with lower than expected sales of Ixchiq in the U.S. The company’s strong cash position and its guidance for 2025, which includes substantial sales revenue and a significant reduction in operating cash burn, further reinforce its financial health.
Additionally, Valneva’s pipeline holds significant potential with several key catalysts on the horizon, including the Phase 3 data readout for VLA15, its Lyme disease vaccine co-developed with Pfizer. Anticipated label expansions for Ixchiq and upcoming data from the Shigella and Zika vaccine candidates add to the company’s long-term growth prospects. These factors, combined with strategic developments and collaborations, underpin Edward White’s optimistic outlook for Valneva, leading to his Buy rating.